Clinical Trial: Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa

This study is not yet open for patient recruitment.

Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

HIV infected people often must take anti-HIV drugs for long periods, leading to long-term drug exposure and toxicity. Interruptions in anti-HIV therapy, also known as structured treatment interruptions (STIs), may have few negative health effects and may be helpful to the overall long-term health of HIV infected people. The purpose of this study is to determine if consecutive STIs are of benefit to HIV infected people who have not previously taken anti-HIV drugs.

Study hypothesis: Immune response to repeated cycles of 2 to 8 weeks off anti-HIV therapy followed by 16 weeks of therapy is not worse than continuous therapy over the same treatment period.

Condition Treatment or Intervention
HIV Infections
 Behavior: Structured treatment interruption
 Drug: Lamivudine
 Drug: Lopinavir/ritonavir
 Drug: Stavudine
 Vaccine: Rabies de novo antigen

MedlinePlus related topics:  AIDS

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Official Title: A Randomized Clinical Trial Assessing Continuous HAART Versus Interrupted HAART in a Resource Poor Clinic

Further Study Details: 
Primary Outcomes: Delay of viral load setpoint of greater than 30,000 copies/ml
Expected Total Enrollment:  90

Expected completion: December 2007

Long-term toxicity and the high cost of medications are two problems faced by HIV infected people taking antiretroviral therapy (ART). Previous studies in HIV infected patients suggest that ART with STIs may decrease drug exposure and lessen long-term drug toxicity, while not sacrificing viral suppression and patient health. This study will determine if ART with STIs can maintain the same level of immune function in HIV infected people as continuous ART. This study will recruit patients in South Africa.

This study will last 3.5 years. At study entry, all participants will begin daily ART consisting of lamivudine, lopinavir/ritonavir, and stavudine. At Month 6, only participants who have responded well to ART (CD4 count greater than 250 cells/mm3 and viral load less than 50 copies/ml at Month 6) will be randomly assigned to one of two groups. Group 1 participants will participate in STIs during therapy, and Group 2 participants will receive continuous therapy. People in Group 1 will have treatment interruptions of 2, 4, 8, 8, and 8 weeks of duration in between 12-week periods of ART. People in Group 2 will continue taking ART throughout the study.

At screening, participants will undergo medical history assessment, a physical exam, and magnetic resonance imaging (MRI) and dual energy x-ray absorptiometry (DEXA) scans. There will be at least 27 study visits occurring approximately every 8 weeks, each lasting 45 to 60 minutes. At each study visit, participants will be asked about their quality of life. Blood collection will occur at selected visits. Participants will receive rabies vaccinations at Weeks 40, 41, and 46. A visit at Week 164 will include MRI and DEXA scans, and participants will receive a rabies vaccine booster.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

  • HIV infected
  • CD4 count of 200 to 350 cells/mm3 within 60 days of starting study treatment
  • Antiretroviral naive. Participants who have received antiretrovirals through postexposure prophylaxis or short course therapy to prevent mother-to-child transmission are eligible for this study.
  • Willing to adhere to study treatment
  • Willing to be followed for the duration of this study

Exclusion Criteria:

  • History of AIDS-defining illness (CDC category C). Patients with a history of pulmonary tuberculosis are not excluded.
  • Newly diagnosed AIDS-defining opportunistic infection or other condition requiring acute therapy at study entry
  • Previous therapy with agents with significant myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic potential within 30 days prior to study entry
  • History of immunomodulatory therapy within 4 weeks prior to screening, or cannot abstain from immunomodulators during the study
  • Previously received rabies vaccine
  • Current alcohol or drug abuse that, in the opinion of the investigator, may interfere with the study
  • Diarrhea (more than 6 stools per day for 7 consecutive days) within 30 days prior to study entry
  • Active or suspected acute hepatitis within 30 days of study entry
  • Bilateral peripheral neuropathy of Grade 2 or higher at screening
  • Inability to tolerate oral medication
  • Any clinical condition that, in the opinion of the investigator, would interfere with the study
  • Pregnancy or breastfeeding

Location Information

Luis J. Montaner, DVM, MSci, DPhil      215-898-3934    montaner@wistar.upenn.edu

South Africa
      University of the Witwatersrand, Johannesburg,  South Africa
Ian M. Sanne, MBBCH, FCP(SA), DTM&H  +27 11 717-2810    ian_sanne@witshealth.co.za 
Wendy Stevens, MBBCH, MMed Haem  +27 11 717-2519 
Ian M. Sanne, MBBCH, FCP(SA), DTM&H,  Principal Investigator
Wendy Stevens, MBBCH, MMed Haem,  Sub-Investigator

Study chairs or principal investigators

Luis J. Montaner, DVM, MSci, DPhil,  Principal Investigator,  The Wistar Institute   
Ian M. Sanne, MBBCH, FCP(SA), DTM&H,  Principal Investigator,  University of the Witwatersrand   

More Information

Click here for more information about lamivudine

Click here for more information about lopinavir/ritonavir

Click here for more information about stavudine

Publications

Buthelezi EP, van der Merwe MT, Lonnroth PN, Gray IP, Crowther NJ. Ethnic differences in the responsiveness of adipocyte lipolytic activity to insulin. Obes Res. 2000 Mar;8(2):171-8.

Punyadeera C, van der Merwe MT, Crowther NJ, Toman M, Schlaphoff GP, Gray IP. Ethnic differences in lipid metabolism in two groups of obese South African women. J Lipid Res. 2001 May;42(5):760-7.

van der Merwe MT, Schlaphoff GP, Crowther NJ, Boyd IH, Gray IP, Joffe BI, Lonnroth PN. Lactate and glycerol release from adipose tissue in lean, obese, and diabetic women from South Africa. J Clin Endocrinol Metab. 2001 Jul;86(7):3296-303.

Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001 Nov 9;15(16):2109-17.

Weissman D, Montaner LJ. Immune reconstitution. Clin Lab Med. 2002 Sep;22(3):719-40. Review.

Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep;182(3):766-75.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002 Jun 27;346(26):2039-46.

Study ID Numbers:  1 R01 AI051986-01A2; R01 AI 51986; Protocol 2411209
Record last reviewed:  January 2005
Last Updated:  January 4, 2005
Record first received:  January 4, 2005
ClinicalTrials.gov Identifier:  NCT00100646
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources